TR201910330T4 - Anti-fosfolin d4 antikoru içeren ilaç. - Google Patents

Anti-fosfolin d4 antikoru içeren ilaç. Download PDF

Info

Publication number
TR201910330T4
TR201910330T4 TR2019/10330T TR201910330T TR201910330T4 TR 201910330 T4 TR201910330 T4 TR 201910330T4 TR 2019/10330 T TR2019/10330 T TR 2019/10330T TR 201910330 T TR201910330 T TR 201910330T TR 201910330 T4 TR201910330 T4 TR 201910330T4
Authority
TR
Turkey
Prior art keywords
antibody
seq
variable region
mouse
cells
Prior art date
Application number
TR2019/10330T
Other languages
English (en)
Turkish (tr)
Inventor
Yamazaki Tomohide
Endo Mayuki
Ishida Koji
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of TR201910330T4 publication Critical patent/TR201910330T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TR2019/10330T 2013-07-30 2014-07-30 Anti-fosfolin d4 antikoru içeren ilaç. TR201910330T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013158258 2013-07-30

Publications (1)

Publication Number Publication Date
TR201910330T4 true TR201910330T4 (tr) 2019-07-22

Family

ID=51493000

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10330T TR201910330T4 (tr) 2013-07-30 2014-07-30 Anti-fosfolin d4 antikoru içeren ilaç.

Country Status (17)

Country Link
US (2) US20160168266A1 (enExample)
EP (1) EP3027656B1 (enExample)
JP (3) JP6431523B2 (enExample)
KR (1) KR102367760B1 (enExample)
CN (1) CN105745226B (enExample)
AU (1) AU2014297217B2 (enExample)
BR (1) BR112016002001B1 (enExample)
CA (1) CA2919736C (enExample)
DK (1) DK3027656T3 (enExample)
ES (1) ES2736324T3 (enExample)
HU (1) HUE044469T2 (enExample)
MX (1) MX381725B (enExample)
PL (1) PL3027656T3 (enExample)
RU (1) RU2709741C2 (enExample)
SG (2) SG10201800592SA (enExample)
TR (1) TR201910330T4 (enExample)
WO (1) WO2015016386A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN104284903B (zh) * 2012-01-31 2020-10-09 Sbi生物技术有限公司 抗磷脂酶d4抗体
PL3027656T3 (pl) * 2013-07-30 2019-10-31 Sbi Biotech Co Ltd Lek zawierający przeciwciało anty-fosfolipazowe D4
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
US12371506B2 (en) 2018-01-12 2025-07-29 Takeda Pharmaceutical Company Limited Subcutaneous administration of anti-CD38 antibodies
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型tlr7の分析

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
US20020146686A1 (en) * 2000-12-07 2002-10-10 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of viral disease using 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
CN104284903B (zh) * 2012-01-31 2020-10-09 Sbi生物技术有限公司 抗磷脂酶d4抗体
PL3027656T3 (pl) * 2013-07-30 2019-10-31 Sbi Biotech Co Ltd Lek zawierający przeciwciało anty-fosfolipazowe D4

Also Published As

Publication number Publication date
EP3027656B1 (en) 2019-06-26
JP2016534022A (ja) 2016-11-04
DK3027656T3 (da) 2019-08-05
PL3027656T3 (pl) 2019-10-31
CN105745226A (zh) 2016-07-06
US20210130493A1 (en) 2021-05-06
MX2016001193A (es) 2016-05-26
ES2736324T3 (es) 2019-12-27
RU2709741C2 (ru) 2019-12-19
RU2016106708A (ru) 2017-09-01
RU2016106708A3 (enExample) 2018-03-30
CA2919736C (en) 2022-03-22
CA2919736A1 (en) 2015-02-05
HUE044469T2 (hu) 2019-10-28
SG10201800592SA (en) 2018-03-28
BR112016002001A2 (pt) 2017-08-29
KR20160034934A (ko) 2016-03-30
CN105745226B (zh) 2020-03-06
JP2019014759A (ja) 2019-01-31
AU2014297217A1 (en) 2016-02-18
AU2014297217B2 (en) 2020-01-16
KR102367760B1 (ko) 2022-02-24
BR112016002001B1 (pt) 2023-04-25
WO2015016386A1 (en) 2015-02-05
JP6431523B2 (ja) 2018-11-28
US20160168266A1 (en) 2016-06-16
JP2019214621A (ja) 2019-12-19
MX381725B (es) 2025-03-13
EP3027656A1 (en) 2016-06-08
JP6843449B2 (ja) 2021-03-17
SG11201600666SA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
KR102503084B1 (ko) 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도
JP7705873B2 (ja) Pvrig結合タンパク質及びその医薬用途
JP6847037B2 (ja) 抗cd73抗体とa2a受容体阻害薬とを含む併用治療薬及びその使用
AU2022204171A1 (en) Anti-PD1 antibodies and their use as therapeutics and diagnostics
EP3936526A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
KR20170080607A (ko) Cd73에 특이적인 결합 분자 및 이의 용도
JP6843449B2 (ja) 抗ホスホリパーゼd4抗体を含む医薬
JP6118345B2 (ja) 抗ホスホリパーゼd4抗体
DK2905335T3 (en) Anti-human dlk-1 antibody with anti-tumor activity in vivo
JP2022553927A (ja) Ilt-2阻害剤での癌の処置
US20250122296A1 (en) Bispecific antibody and use thereof
RU2741802C2 (ru) АНТИТЕЛО К Myl9
CN121532427A (zh) 抗cd40l/抗cd28双特异性抗体及其用途
CN119552247A (zh) 抗cd25抗体及其医药用途
KR20260047589A (ko) Btn3a 결합 단백질 및 이의 의학적 용도
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK1257725B (en) Anti-pd1 antibodies and their use as therapeutics and diagnostics
HK1257725A1 (en) Anti-pd1 antibodies and their use as therapeutics and diagnostics
HK40011075A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
HK40011075B (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EA040773B1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации